A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors
Status:
Recruiting
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
This is a first in human, open-label, dose escalation and expansion Phase I study of
SIM1811-03 in adult patients with advanced tumors. SIM1811-03 is a first-in-class IgG1-based
humanized anti-tumor necrosis factor type 2 receptor (TNFR2) monoclonal antibody for the
treatment of malignant tumors.